About £3.7 million ($4.9 million) of proceeds from the placement would go toward the acquisition, while remaining funds will support assay development validation, and working capital.
Women with BRCA1 or BRCA2 mutations tell the Washington Post how learning their status has affected their life choices.
In an increasingly diverse field of sequencing assays, Genentech researchers believe they have achieved notable sensitivity, with high multiplexing capability and relatively low cost.
The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
New research suggests some individuals with germline BRCA1/2 mutations who develop cancer may benefit from tumor BRCA functionality testing prior to treatment.
Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
In a retrospective cohort study of Lynch syndrome patients, researchers found that cancer onset varied both by which gene was mutated and how it was altered.
NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.
The Korean molecular diagnostics startup is planning to launch the new offering in Europe, as well as China and other Southeast Asian countries.
The Stanford University and Fox Chase Cancer Center team found that some mutations dramatically increased cancer risk, while others had a more modest effect.
Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.
Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.
Researchers link genetic links between education and smoking and longevity.
In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.